Oxford Gene Technology, a UK firm perhaps better known for its menu of chromosomal microarrays and foundational array IP, has seen its protein array platform emerge from the shadows in recent weeks after signing an agreement that gives its main partner in Asia the ability to offer the arrays directly.
In addition, OGT recently provided an update on tests that have been developed, in part, using the platform, such as an assay for systemic lupus erythematosus.